

## Biosafety Documentation: *iCell<sup>®</sup> Hepatocytes 2.0*

Catalog Number(s): C1023, C1090  
Donor ID Number: 01279

### **Cell Source and Biosafety Level Classification**

iCell<sup>®</sup> Hepatocytes 2.0 are human cells differentiated from a master bank of stably induced pluripotent stem (iPS) cells. Cellular Dynamics International, Inc. (CDI) classifies these cells as Biosafety Level 1 (BSL1) based on the United States Centers for Disease Control and Prevention publication: *Biosafety in Microbiological and Biomedical Laboratories*. We recommend handling iCell Hepatocytes 2.0 according to the biosafety guidelines applicable in your region.

### **Reprogramming**

The iPS cell lines were generated from human peripheral blood through ectopic expression of reprogramming factors (i.e. Oct4, Sox2, Nanog, Lin28, Klf4, L-Myc, SV40LT) by episomal transfection. Following reprogramming, no episomal plasmids were detected by PCR in the iPS cell line.

### **Engineering**

The iPS cell clones were engineered using nuclease-mediated methodologies to exhibit neomycin resistance under the control of a hepatic-specific promoter. Puromycin resistance was also included in the targeting vector to allow selection of the iPS cell clones. None of the engineering vectors used contain oncogenes.

### **Infectious Disease Testing**

The iPS cell line is negative for HBV, HCV, HIV-1, and HIV-2.

### **Reference(s)**

CDI Technical Support: fcdi-support@fujifilm.com; US and Canada toll-free +1 (877) 320-6688 or +1 (608) 310-5100.